SOHO 2024 live congress feed

Stay up to date with the latest developments in Multiple Myeloma from the SOHO 2024 Annual Meeting with our live social media coverage.

CONGRESS | #SOHO2024 | POSTER@SagarLonialMD @WinshipAtEmory shares data from the CC-220-MM-001 trial of IberVd in transplant-ineligible NDMM.
ORR 100%, ≥CR 56.25%, MRD-neg 43%, infections 76.5%, Grade 3/4 infections 35.3%, neutropenia 35.3%, Grade 3/4 neutropenia 23.5%.#mmsm… pic.twitter.com/oT9xvGXW88

— Multiple Myeloma Hub (@MM_Hub) September 6, 2024

CONGRESS | #SOHO2024 | POSTER@DrKrinaPatel @MDAndersonNews shares results from a subanalysis of data from Black patients enrolled in the KarMMa-3 study.
ORR 89%, sCR 50%, median DoR 17.5 mo, median PFS 20.3 mo, 9-mo PFS 77%, CRS 82%, iiNT 12%. The clinical benefit of ide-cel… pic.twitter.com/XIwsCdf6Q9

— Multiple Myeloma Hub (@MM_Hub) September 6, 2024

CONGRESS | #SOHO2024
Meletios Dimopoulos @thanosdimop presents an analysis of MRD from the phase III PERSEUS study of D-VRd for transplant-eligible NDMM. Sustained MRD-neg rates were improved with D-VRd across all subgroups and at >12 months were approximately double compared to… pic.twitter.com/b3P5K3c7QC

— Multiple Myeloma Hub (@MM_Hub) September 5, 2024

CONGRESS | #SOHO2024@DoctorAKrishnan @cityofhopeoc discusses sequencing and resistance associated with T-cell engagers in #MultipleMyeloma. Krishnan suggests methods to effectively sequence T-cell engagers using different targets and modalities, with potential for future… pic.twitter.com/VfcMVRg2M6

— Multiple Myeloma Hub (@MM_Hub) September 5, 2024

CONGRESS | #SOHO2024
Meletios Dimopoulos @thanosdimop presents on the treatment options for first relapse in #MultipleMyeloma; sharing data from the latest clinical trials of approved and investigational agents. #mmsm #myeloma pic.twitter.com/56vO5YjdkS

— Multiple Myeloma Hub (@MM_Hub) September 5, 2024

CONGRESS | #SOHO2024
Suzanne Lentzsch @Slentzsch @columbiacancer discusses the definition and treatment of HR-NDMM and functional HR #MultipleMyeloma. High-remission rates are possible but duration is often short, highlighting an unmet need amongst these patients.#mmsm #myeloma pic.twitter.com/lugFWzF3f5

— Multiple Myeloma Hub (@MM_Hub) September 5, 2024

CONGRESS | #SOHO2024
Saad Usmani @szusmani @MSKCancerCenter argues that there are too many unknowns for CAR T-cell therapies in earlier lines to apply this to all patients, furthermore there are novel therapies being investigated for early relapsed setting that may influence… pic.twitter.com/qDmvM3Eeq4

— Multiple Myeloma Hub (@MM_Hub) September 5, 2024

CONGRESS | #SOHO2024@DrKrinaPatel @MDAndersonNews debates for the use of CAR T in the early relapsed setting, concluding that there is a place for CAR T in both the early and late relapsed setting, with latest data showing evidence for unprecedented high efficacy rates in both… pic.twitter.com/ROvvq420gF

— Multiple Myeloma Hub (@MM_Hub) September 5, 2024

CONGRESS | #SOHO2024@AjayNookaMD @EmoryMedicine discusses whether quadruplet regimens should be used for all patients with NDMM; concluding that upfront quad therapies are the standard of care for both transplant eligible and ineligible patients. #mmsm #myeloma pic.twitter.com/skqe4bXukY

— Multiple Myeloma Hub (@MM_Hub) September 5, 2024

Only 1 day to go! 

The #MultipleMyeloma Hub will be covering #SOHO2024.

Sep 4–7  
Houston, US, and online

We’ll be providing live social media coverage.
Keep an eye on our socials to see the latest updates! #mmsm @SocietyofHemOnc pic.twitter.com/dMwAWG5uFC

— Multiple Myeloma Hub (@MM_Hub) September 3, 2024